SK Life Science, Inc.
$5.1M 20,538 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc. reported $5,133,141.31 across General Payments, Research, and Ownership to 13,236 physicians and teaching hospitals across 13,623 transactions.
- $5.1M Top quartile payer
- All-tracks total
- 13,623 Top 10% volume
- Transactions
- 13,236 Top 10% reach
- Recipients
- −$1.4M
- General Payments vs PY2023
Intercept Pharmaceuticals, Inc. reported $5,133,141.31 across all CMS Open Payments tracks (General + Research + Ownership) to 13,236 physicians and teaching hospitals in Program Year 2024 - ranking #269 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,765,551.26, averaging $387.82 per recipient.
How Intercept Pharmaceuticals, Inc.'s $5.1M all-tracks total breaks down
Intercept Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
B
87/100
Total payments
D
57/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer intercept-pharmaceuticals-inc Intercept Pharmaceuticals, Inc.
$5.1M · #269/1,925 · 0.0% industry · PY2024
- TOT $5.1M
- RANK #269
- SHARE 0.0%
- TXN 13,623
- RCP 13,236
- CAT 7
- GEN $2.8M
- ΔGEN −$1.4M
- TOP1 31.9%
- PY 2024
Volume peers
Nearest volume peer: SK Life Science, Inc. ($5.1M)
Intercept Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Intercept Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $1.4M (−33.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: INTERCEPT PHARMACEUTICALS, INC.PY2023: INTERCEPT PHARMACEUTICALS, INC.PY2024: Intercept Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $4,182,258.34
- PY2024
- $2,765,551.26
What the Data Shows for Intercept Pharmaceuticals, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Intercept Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Consulting Fee" leads the 7-category general-payment breakdown below at $1.5M (55.4% of General Payments, 113 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 7 types of general payments, Intercept Pharmaceuticals, Inc.'s largest category was "Consulting Fee" at $1.5M - 55.4% of General Payments.
Intercept Pharmaceuticals, Inc. reports 7 general-payment categories - the top three are Consulting Fee (55.4%), Compensation for Faculty or Speaker (Medical Education) (26.6%), and Food and Beverage (10.8%). The remaining 4 categories make up 7.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Intercept Pharmaceuticals, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $1.5M | 113 | 55.4% |
| Compensation for Faculty or Speaker (Medical Education) | $736.6K | 267 | 26.6% |
| Food and Beverage | $298.2K | 12,596 | 10.8% |
| Honoraria | $98.5K | 65 | 3.6% |
| Travel and Lodging | $76.4K | 152 | 2.8% |
| Space Rental or Facility Fees | $23.5K | 9 | 0.8% |
| Education | $415.34 | 34 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,379,968.00 (49.9%) of $2,765,551.26 in this company's General Payments records across 6,512 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Intercept Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Haytham Elgammal
$883,348.88 across 16 reported transactions
- 2
University Of Iowa Hosp & Clinics
$212,853.17 across 27 reported transactions
- 3
Robert Gish
$134,404.04 across 53 reported transactions
- 4
Robert Brown
$76,795.91 across 10 reported transactions
- 5
Nezam Afdhal
$72,566.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Intercept Pharmaceuticals, Inc. ranks #269 of 1,925 by total payments (top 14% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #968 of 1,838 by HHI (bottom 47% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- DentalEZ Alabama, Inc. : $5.9K total payments, HHI 1168
- Hollister Incorporated : $45.3K total payments, HHI 1167
- Kamada Ltd. : $83.4K total payments, HHI 1166
- Pulpdent Corporation : $80.0K total payments, HHI 1162
- Optos, Inc. : $585.3K total payments, HHI 1153
- HemoSonics LLC : $100.7K total payments, HHI 1152
- Intercept Pharmaceuticals, Inc. (this company) : $2.8M total payments, HHI 1149
- Asensus Surgical, Inc. : $207.1K total payments, HHI 1147
- Alcresta Therapeutics, Inc. : $170.2K total payments, HHI 1141
- Pathway Medical Partners, LLC : $66.0K total payments, HHI 1140
- Visionix USA, Inc : $108.9K total payments, HHI 1138
- Anika Therapeutics, Inc. : $1.1M total payments, HHI 1135
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Intercept Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Intercept Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Intercept Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Pristine Surgical LLC
$5.1M 5 recipients
Compare payment profiles
BrainScope Company, Inc.
$5.1M 25 recipients
Compare payment profiles
Actelion Pharmaceuticals US, Inc.
$5.2M 31,311 recipients
Compare payment profiles
ADC Therapeutics America, Inc.
$5.1M 4,269 recipients
Compare payment profiles
Jcbd, LLC
$5.1M 10 recipients
Compare payment profiles
Put this to use
Intercept Pharmaceuticals, Inc. ranks #269 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Intercept Pharmaceuticals, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Intercept Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.